These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 15206668)

  • 41. LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone.
    Pullar IA; Carney SL; Colvin EM; Lucaites VL; Nelson DL; Wedley S
    Eur J Pharmacol; 2000 Oct; 407(1-2):39-46. PubMed ID: 11050288
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Binding of 5-HT1A receptor and 5-HT transporter ligands in rat cortex and hippocampus following cholinergic and serotonergic lesions.
    Lawrence JA; Olverman HJ; Shirakawa K; Kelly JS; Butcher SP
    Brain Res; 1993 May; 612(1-2):326-9. PubMed ID: 7687192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual NK(1) antagonists--serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives.
    Ryckmans T; Berton O; Grimée R; Kogej T; Lamberty Y; Pasau P; Talaga P; Genicot C
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3195-8. PubMed ID: 12372532
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pharmacogenetic study of escitalopram in autism spectrum disorders.
    Owley T; Brune CW; Salt J; Walton L; Guter S; Ayuyao N; Gibbons RD; Leventhal BL; Cook EH
    Autism Res; 2010 Feb; 3(1):1-7. PubMed ID: 20020537
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain.
    Honig G; Jongsma ME; van der Hart MC; Tecott LH
    PLoS One; 2009 Aug; 4(8):e6797. PubMed ID: 19710918
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serotonin transporter gene and escitalopram: depressing medical science.
    Braillon A
    Eur J Clin Pharmacol; 2020 Nov; 76(11):1621-1622. PubMed ID: 32591942
    [No Abstract]   [Full Text] [Related]  

  • 47. Escitalopram's inflammatory effect on the mammalian macrophages and its intracellular mechanism of action.
    Önal HT; Yetkin D; Ayaz F
    Prog Neuropsychopharmacol Biol Psychiatry; 2023 Jul; 125():110762. PubMed ID: 37031947
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alkaloids from Boophane disticha with affinity to the serotonin transporter in rat brain.
    Sandager M; Nielsen ND; Stafford GI; van Staden J; Jäger AK
    J Ethnopharmacol; 2005 Apr; 98(3):367-70. PubMed ID: 15814274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of escitalopram on vagally mediated cardiovascular function in healthy participants: implications for understanding differential age-related, treatment emergent effects.
    Kemp AH; Outhred T; Saunders S; Brunoni AR; Nathan PJ; Malhi GS
    Psychopharmacology (Berl); 2014 Jun; 231(11):2281-90. PubMed ID: 24337078
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy.
    Eichentopf L; Hiemke C; Conca A; Engelmann J; Gerlach M; Havemann-Reinecke U; Hefner G; Florio V; Kuzin M; Lieb K; Reis M; Riemer TG; Serretti A; Schoretsanitis G; Zernig G; Gründer G; Hart XM
    Front Psychiatry; 2022; 13():972141. PubMed ID: 36325531
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Micelle enhanced fluorimetric and thin layer chromatography densitometric methods for the determination of (+/-) citalopram and its S-enantiomer escitalopram.
    Taha EA; Salama NN; Wang S
    Anal Chem Insights; 2009 Apr; 4():1-9. PubMed ID: 19652757
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changing the Way We Think About (and With) Antidepressants.
    Novick AM; Ross DA
    Biol Psychiatry; 2018 Aug; 84(4):e27-e28. PubMed ID: 30071948
    [No Abstract]   [Full Text] [Related]  

  • 53. Stereoisomers in Psychiatry: The Case of Escitalopram.
    Burke WJ; Kratochvil CJ
    Prim Care Companion J Clin Psychiatry; 2002 Feb; 4(1):20-24. PubMed ID: 15014731
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Escitalopram: a review of its use in the management of major depressive disorder in adults.
    Garnock-Jones KP; McCormack PL
    CNS Drugs; 2010 Sep; 24(9):769-96. PubMed ID: 20806989
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Escitalopram: a review of its use in the management of anxiety disorders.
    Dhillon S; Scott LJ; Plosker GL
    CNS Drugs; 2006; 20(9):763-90. PubMed ID: 16953656
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Escitalopram: a review of its use in the management of major depressive disorder.
    Murdoch D; Keam SJ
    Drugs; 2005; 65(16):2379-404. PubMed ID: 16266205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique.
    Rausch JL; Corley KM; Hobby HM
    J Clin Psychopharmacol; 2004 Apr; 24(2):209-13. PubMed ID: 15206668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.
    Sánchez C; Bergqvist PB; Brennum LT; Gupta S; Hogg S; Larsen A; Wiborg O
    Psychopharmacology (Berl); 2003 Jun; 167(4):353-62. PubMed ID: 12719960
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine].
    Owens JM; Knight DL; Nemeroff CB
    Encephale; 2002; 28(4):350-5. PubMed ID: 12232544
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.